- Home
- RARE vs UTG Comparison
RARE vs UTG Comparison
Compare RARE & UTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RARE | UTG |
|---|---|---|
| Founded | 2010 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.3B |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | RARE | UTG |
|---|---|---|
| Price | $36.37 | $37.62 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 15 | 0 |
| Target Price | ★ $85.20 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 317.8K |
| Earning Date | 11-04-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.28% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 9.86 |
| Revenue | ★ $630,598,000.00 | $96,107,593.00 |
| Revenue This Year | $19.09 | N/A |
| Revenue Next Year | $20.62 | N/A |
| P/E Ratio | ★ N/A | $3.20 |
| Revenue Growth | ★ 20.63 | 8.35 |
| 52 Week Low | $25.81 | $25.26 |
| 52 Week High | $50.00 | $35.29 |
Technical Indicators
Market Signals| Indicator | RARE | UTG |
|---|---|---|
| Relative Strength Index (RSI) | 62.08 | 48.95 |
| Support Level | $33.16 | $37.25 |
| Resistance Level | $34.77 | $38.59 |
| Average True Range (ATR) | 1.52 | 0.73 |
| MACD | 0.36 | 0.13 |
| Stochastic Oscillator | 83.52 | 64.20 |
Price Performance
Historical ComparisonAbout RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About UTG Reaves Utility Income Fund of Beneficial Interest
Reaves Utility Income Fund is a closed-end management investment company. The company's investment objective is to provide a high level of after-tax income and total return consisting of tax-advantaged dividend income and capital appreciation. It invests a portion of its total assets in securities of utility companies, which may include companies in the electric, gas, water, telecommunications sectors, as well as other companies engaged in other infrastructure operations.